275 related articles for article (PubMed ID: 33037866)
1. The EUTOS long-term survival score predicts disease-specific mortality and molecular responses among patients with chronic myeloid leukemia in a practice-based cohort.
Sato E; Iriyama N; Tokuhira M; Takaku T; Ishikawa M; Nakazato T; Sugimoto KJ; Fujita H; Kimura Y; Fujioka I; Asou N; Komatsu N; Kizaki M; Hatta Y; Kawaguchi T
Cancer Med; 2020 Dec; 9(23):8931-8939. PubMed ID: 33037866
[TBL] [Abstract][Full Text] [Related]
2. Is the Sokal or EUTOS long-term survival (ELTS) score a better predictor of responses and outcomes in persons with chronic myeloid leukemia receiving tyrosine-kinase inhibitors?
Zhang XS; Gale RP; Huang XJ; Jiang Q
Leukemia; 2022 Feb; 36(2):482-491. PubMed ID: 34413457
[TBL] [Abstract][Full Text] [Related]
3. [A scoring system to predict molecular responses in patients with chronic myeloid leukemia in the chronic phase receiving initial imatinib therapy].
Li ZY; Zhang MY; Zhang XS; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2023 Feb; 44(2):106-111. PubMed ID: 36948863
[No Abstract] [Full Text] [Related]
4. EUTOS CML prognostic scoring system predicts ELN-based 'event-free survival' better than Euro/Hasford and Sokal systems in CML patients receiving front-line imatinib mesylate.
Uz B; Buyukasik Y; Atay H; Kelkitli E; Turgut M; Bektas O; Eliacik E; Isik A; Aksu S; Goker H; Sayinalp N; Ozcebe OI; Haznedaroglu IC
Hematology; 2013 Sep; 18(5):247-52. PubMed ID: 23540886
[TBL] [Abstract][Full Text] [Related]
5. Validation of the EUTOS Long-Term Survival Score in Chinese Chronic Myeloid Leukemia Patients Treated with Imatinib: A Multicenter Real-World Study.
Yang X; Bai Y; Shi M; Zhang W; Niu J; Wu C; Zhang L; Xu Z; Liu X; Chen Y; Sun K
Cancer Manag Res; 2020; 12():1293-1301. PubMed ID: 32110103
[TBL] [Abstract][Full Text] [Related]
6. Changing Treatment May Affect the Predictive Ability of European Treatment Outcome Study Scoring for the Prognosis of Patients with Chronic Myeloid Leukemia.
Huang J; Wang L; Chen L; Qun H; Yajing X; Fangping C; Xielan Z
Turk J Haematol; 2017 Mar; 34(1):10-15. PubMed ID: 27751981
[TBL] [Abstract][Full Text] [Related]
7. Can the Use of Bone Marrow Parameters Improve the Efficacy of Risk Prediction Scores in Chronic Myeloid Leukemia in Imatinib Era?
Kanakasetty GB; Thanky AH; Kuntegowdanahalli L; Dasappa L; Jacob L; Mallekavu SB; Lakkavalli R; Kadabur L; Antapura R
Clin Lymphoma Myeloma Leuk; 2017 Jun; 17(6):375-381. PubMed ID: 28502460
[TBL] [Abstract][Full Text] [Related]
8. Chronic myeloid leukemia patients in Tunisia: epidemiology and outcome in the imatinib era (a multicentric experience).
Ben Lakhal R; Ghedira H; Bellaaj H; Ben Youssef Y; Menif S; Manai Z; Bedoui M; Lakhal A; M'Sadek F; Elloumi M; Khélif A; Ben Romdhane N; Laatiri MA; Ben Othmen T; Meddeb B
Ann Hematol; 2018 Apr; 97(4):597-604. PubMed ID: 29305630
[TBL] [Abstract][Full Text] [Related]
9. The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia.
Pfirrmann M; Clark RE; Prejzner W; Lauseker M; Baccarani M; Saussele S; Guilhot F; Heibl S; Hehlmann R; Faber E; Turkina A; Ossenkoppele G; Höglund M; Zaritskey A; Griskevicius L; Olsson-Strömberg U; Everaus H; Koskenvesa P; Labar B; Sacha T; Zackova D; Cervantes F; Colita A; Zupan I; Bogdanovic A; Castagnetti F; Guilhot J; Hasford J; Hochhaus A; Hoffmann VS
Leukemia; 2020 Aug; 34(8):2138-2149. PubMed ID: 32601376
[TBL] [Abstract][Full Text] [Related]
10. The Hasford Score May Predict Molecular Response in Chronic Myeloid Leukemia Patients: A Single Institution Experience.
Dybko J; Jaźwiec B; Haus O; Urbaniak-Kujda D; Kapelko-Słowik K; Wróbel T; Lonc T; Sawicki M; Mędraś E; Kaczmar-Dybko A; Kuliczkowski K
Dis Markers; 2016; 2016():7531472. PubMed ID: 27818567
[TBL] [Abstract][Full Text] [Related]
11. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.
Hochhaus A; Baccarani M; Silver RT; Schiffer C; Apperley JF; Cervantes F; Clark RE; Cortes JE; Deininger MW; Guilhot F; Hjorth-Hansen H; Hughes TP; Janssen JJWM; Kantarjian HM; Kim DW; Larson RA; Lipton JH; Mahon FX; Mayer J; Nicolini F; Niederwieser D; Pane F; Radich JP; Rea D; Richter J; Rosti G; Rousselot P; Saglio G; Saußele S; Soverini S; Steegmann JL; Turkina A; Zaritskey A; Hehlmann R
Leukemia; 2020 Apr; 34(4):966-984. PubMed ID: 32127639
[TBL] [Abstract][Full Text] [Related]
12. Outcome prediction of chronic myeloid leukemia (CML) in children.
Leung WY; Cheuk DK; Cheng FW; Leung AW; Chiu KH; Ho KK; Li CH; Chan GC
Ann Hematol; 2022 Aug; 101(8):1677-1688. PubMed ID: 35641639
[TBL] [Abstract][Full Text] [Related]
13. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial.
Saussele S; Richter J; Guilhot J; Gruber FX; Hjorth-Hansen H; Almeida A; Janssen JJWM; Mayer J; Koskenvesa P; Panayiotidis P; Olsson-Strömberg U; Martinez-Lopez J; Rousselot P; Vestergaard H; Ehrencrona H; Kairisto V; Machová Poláková K; Müller MC; Mustjoki S; Berger MG; Fabarius A; Hofmann WK; Hochhaus A; Pfirrmann M; Mahon FX;
Lancet Oncol; 2018 Jun; 19(6):747-757. PubMed ID: 29735299
[TBL] [Abstract][Full Text] [Related]
14. [Chronic myeloid leukemia: update on treatment and survival prediction].
Sasaki K
Rinsho Ketsueki; 2020; 61(9):1179-1186. PubMed ID: 33162514
[TBL] [Abstract][Full Text] [Related]
15. Introduction of second-generation tyrosine kinase inhibitors may reduce the prognostic impact of high-risk patients, according to the European treatment and outcome study (EUTOS) score.
Sato E; Iriyama N; Tokuhira M; Takaku T; Ishikawa M; Nakazato T; Sugimoto KJ; Fujita H; Fujioka I; Asou N; Komatsu N; Kizaki M; Hatta Y; Kawaguchi T
Leuk Lymphoma; 2018 May; 59(5):1105-1112. PubMed ID: 28838287
[TBL] [Abstract][Full Text] [Related]
16. Long-Term Outcomes with Sequential Tyrosine Kinase Inhibitors Treatment in Chronic Myeloid Leukemia Patients.
Towachiraporna S; Punnachet T; Hantrakun N; Piriyakhuntorn P; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Rattarittamrong E; Norasetthada L; Tantiworawit A
Asian Pac J Cancer Prev; 2023 May; 24(5):1513-1520. PubMed ID: 37247270
[TBL] [Abstract][Full Text] [Related]
17. Prognostic discrimination for early chronic phase chronic myeloid leukemia in imatinib era: comparison of Sokal, Euro, and EUTOS scores in Korean population.
Yahng SA; Jang EJ; Choi SY; Lee SE; Kim SH; Kim DW
Int J Hematol; 2014 Aug; 100(2):132-40. PubMed ID: 24879034
[TBL] [Abstract][Full Text] [Related]
18. [Clinical significance of Sokal, Hasford and EUTOS prognostic scoring systems in chronic myeloid leukemia].
Feng G; Wang J; Jiang Y; Li Y; Ding M; Wang N; Wang X
Zhonghua Xue Ye Xue Za Zhi; 2014 Aug; 35(8):743-6. PubMed ID: 25152126
[TBL] [Abstract][Full Text] [Related]
19. Presence of novel compound BCR-ABL mutations in late chronic and advanced phase imatinib sensitive CML patients indicates their possible role in CML progression.
Akram AM; Iqbal Z; Akhtar T; Khalid AM; Sabar MF; Qazi MH; Aziz Z; Sajid N; Aleem A; Rasool M; Asif M; Aloraibi S; Aljamaan K; Iqbal M
Cancer Biol Ther; 2017 Apr; 18(4):214-221. PubMed ID: 28278078
[TBL] [Abstract][Full Text] [Related]
20. Impact of risk score calculations in choosing front-line tyrosine kinase inhibitors for patients with newly diagnosed chronic myeloid leukemia in the chronic phase.
Hu B; Savani BN
Eur J Haematol; 2014 Sep; 93(3):179-86. PubMed ID: 24766312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
